-
1 Comment
Yifan Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 18.4% below its 200 day moving average.
From a valuation standpoint, the stock is 52.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.
Yifan Pharmaceutical Co., Ltd's total revenue sank by 9.5% to $1B since the same quarter in the previous year.
Its net income has dropped by 64.6% to $57M since the same quarter in the previous year.
Finally, its free cash flow fell by 236.5% to $-210M since the same quarter in the previous year.
Based on the above factors, Yifan Pharmaceutical Co., Ltd gets an overall score of 1/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ISIN | CNE000001K65 |
| Market Cap | 17B |
|---|---|
| PE Ratio | 38.86 |
| Target Price | 18 |
| Dividend Yield | 0.7% |
| Beta | 0.73 |
Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 and original B5. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Hangzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002019.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
